GlobeNewswire Inc.··Delveinsight65+ Pharma Giants Race to Dominate COPD Market with Next-Gen Biologics
Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.
AMGNPFESNYAZNUPB+2clinical trialsbiologics